Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2019-07-22 Regulatory Filings
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
기타경영사항(특허권취득)(자율공시)(신규한 비브리오균 특이 박테리오파지 VP4 및 이를 포함하는 항균 조성물 외 4건)
Regulatory Filings Classification · 1% confidence The document is a voluntary disclosure (자율공시) from Optipharm regarding the acquisition of five patents related to bacteriophages. It details the patent names, descriptions, and utilization plans. Since this is a specific corporate announcement regarding business operations (intellectual property acquisition) that does not fit into financial reporting, M&A, or governance categories, it falls under the general regulatory filing category.
2019-07-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required under the Capital Markets Act when a person or entity acquires a significant stake (typically 5% or more) in a company or experiences changes in their holdings. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2019-07-05 Korean
기타경영사항(특허권취득)(자율공시)(신규한 ESBL 생성 대장균 특이 박테리오파지 ECO4 및 이를 포함하는 항균 조성물 외 4건)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from Optipharm regarding the acquisition of five patents related to bacteriophage technology. It is a voluntary disclosure (자율공시) filed with the Korean stock exchange. Since it does not fit into specific categories like financial reports, M&A, or director dealings, it falls under the general regulatory filing category.
2019-06-21 Korean
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Optipharm' covering the period from January 1, 2019, to March 31, 2019. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-15 Korean
기타경영사항(특허권취득)(자율공시)(외래 단백질 발현 증가를 위한 재조합 전이 벡터)
Regulatory Filings Classification · 1% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by Optipharm. It details the patent name, content, and utilization plan. Since this is a specific regulatory announcement regarding corporate developments that does not fit into financial reporting, dividend announcements, or management changes, it falls under the general regulatory filing category.
2019-04-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) to report insider trading or changes in shareholdings by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2019-04-18 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.